Sano, D.; Liu, N.; Knowles, S.; MacEwan, J.P.; Wang, S.; Wogen, J.; Yu, K.S.; Lee, S.T.
Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis. Curr. Oncol. 2024, 31, 2598-2609.
https://doi.org/10.3390/curroncol31050195
AMA Style
Sano D, Liu N, Knowles S, MacEwan JP, Wang S, Wogen J, Yu KS, Lee ST.
Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis. Current Oncology. 2024; 31(5):2598-2609.
https://doi.org/10.3390/curroncol31050195
Chicago/Turabian Style
Sano, Dahlia, Nicholas Liu, Scott Knowles, Joanna P. MacEwan, Shu Wang, Jenifer Wogen, Kristina S. Yu, and Seung Tae Lee.
2024. "Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis" Current Oncology 31, no. 5: 2598-2609.
https://doi.org/10.3390/curroncol31050195
APA Style
Sano, D., Liu, N., Knowles, S., MacEwan, J. P., Wang, S., Wogen, J., Yu, K. S., & Lee, S. T.
(2024). Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis. Current Oncology, 31(5), 2598-2609.
https://doi.org/10.3390/curroncol31050195
